ANNOVIS BIO (ANVS) Fundamental Analysis & Valuation

NYSE:ANVS • US03615A1088

Current stock price

2.6 USD
-0.07 (-2.62%)
At close:
2.6 USD
0 (0%)
After Hours:

This ANVS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ANVS Profitability Analysis

1.1 Basic Checks

  • ANVS had negative earnings in the past year.
  • ANVS had a negative operating cash flow in the past year.
  • In the past 5 years ANVS always reported negative net income.
  • ANVS had a negative operating cash flow in each of the past 5 years.
ANVS Yearly Net Income VS EBIT VS OCF VS FCFANVS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M -50M

1.2 Ratios

  • ANVS has a Return On Assets of -136.87%. This is amonst the worse of the industry: ANVS underperforms 82.34% of its industry peers.
  • Looking at the Return On Equity, with a value of -171.23%, ANVS is doing worse than 67.18% of the companies in the same industry.
Industry RankSector Rank
ROA -136.87%
ROE -171.23%
ROIC N/A
ROA(3y)-288.01%
ROA(5y)-193.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ANVS Yearly ROA, ROE, ROICANVS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500 -1K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ANVS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANVS Yearly Profit, Operating, Gross MarginsANVS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025

7

2. ANVS Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, ANVS has more shares outstanding
  • The number of shares outstanding for ANVS has been increased compared to 5 years ago.
  • ANVS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ANVS Yearly Shares OutstandingANVS Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
ANVS Yearly Total Debt VS Total AssetsANVS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

2.2 Solvency

  • Based on the Altman-Z score of -4.07, we must say that ANVS is in the distress zone and has some risk of bankruptcy.
  • ANVS has a Altman-Z score (-4.07) which is in line with its industry peers.
  • There is no outstanding debt for ANVS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.07
ROIC/WACCN/A
WACCN/A
ANVS Yearly LT Debt VS Equity VS FCFANVS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M

2.3 Liquidity

  • ANVS has a Current Ratio of 5.80. This indicates that ANVS is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of ANVS (5.80) is better than 61.42% of its industry peers.
  • A Quick Ratio of 5.80 indicates that ANVS has no problem at all paying its short term obligations.
  • ANVS has a better Quick ratio (5.80) than 62.19% of its industry peers.
Industry RankSector Rank
Current Ratio 5.8
Quick Ratio 5.8
ANVS Yearly Current Assets VS Current LiabilitesANVS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

1

3. ANVS Growth Analysis

3.1 Past

  • ANVS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 23.08%, which is quite impressive.
EPS 1Y (TTM)23.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.3%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, ANVS will show a very strong growth in Earnings Per Share. The EPS will grow by 25.28% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-1.82%
EPS Next 2Y4.37%
EPS Next 3Y-14.68%
EPS Next 5Y25.28%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ANVS Yearly Revenue VS EstimatesANVS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
ANVS Yearly EPS VS EstimatesANVS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4 6 -6

0

4. ANVS Valuation Analysis

4.1 Price/Earnings Ratio

  • ANVS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ANVS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANVS Price Earnings VS Forward Price EarningsANVS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANVS Per share dataANVS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

  • A cheap valuation may be justified as ANVS's earnings are expected to decrease with -14.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.37%
EPS Next 3Y-14.68%

0

5. ANVS Dividend Analysis

5.1 Amount

  • No dividends for ANVS!.
Industry RankSector Rank
Dividend Yield 0%

ANVS Fundamentals: All Metrics, Ratios and Statistics

ANNOVIS BIO

NYSE:ANVS (3/20/2026, 8:04:00 PM)

After market: 2.6 0 (0%)

2.6

-0.07 (-2.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-13
Earnings (Next)05-11
Inst Owners20.17%
Inst Owner Change70.81%
Ins Owners15.41%
Ins Owner Change3.94%
Market Cap73.74M
Revenue(TTM)N/A
Net Income(TTM)-28.85M
Analysts82
Price Target14.03 (439.62%)
Short Float %12.25%
Short Ratio6.5
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-15.15%
Min EPS beat(2)-18.93%
Max EPS beat(2)-11.37%
EPS beat(4)2
Avg EPS beat(4)0.93%
Min EPS beat(4)-18.93%
Max EPS beat(4)22.06%
EPS beat(8)4
Avg EPS beat(8)4.16%
EPS beat(12)5
Avg EPS beat(12)-26.9%
EPS beat(16)7
Avg EPS beat(16)-20.78%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.38
P/tB 4.38
EV/EBITDA N/A
EPS(TTM)-1.4
EYN/A
EPS(NY)-1.43
Fwd EYN/A
FCF(TTM)-0.9
FCFYN/A
OCF(TTM)-0.9
OCFYN/A
SpS0
BVpS0.59
TBVpS0.59
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -136.87%
ROE -171.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-288.01%
ROA(5y)-193.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.8
Quick Ratio 5.8
Altman-Z -4.07
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.3%
EPS Next Y-1.82%
EPS Next 2Y4.37%
EPS Next 3Y-14.68%
EPS Next 5Y25.28%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-11.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-55.34%
EBIT Next 3Y-80.63%
EBIT Next 5Y45.47%
FCF growth 1Y-17.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.01%
OCF growth 3YN/A
OCF growth 5YN/A

ANNOVIS BIO / ANVS Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ANNOVIS BIO?

ChartMill assigns a fundamental rating of 2 / 10 to ANVS.


What is the valuation status of ANNOVIS BIO (ANVS) stock?

ChartMill assigns a valuation rating of 0 / 10 to ANNOVIS BIO (ANVS). This can be considered as Overvalued.


What is the profitability of ANVS stock?

ANNOVIS BIO (ANVS) has a profitability rating of 0 / 10.


What is the earnings growth outlook for ANNOVIS BIO?

The Earnings per Share (EPS) of ANNOVIS BIO (ANVS) is expected to decline by -1.82% in the next year.